Leaflet ERIBULIN EVER PHARMA 0.44mg / ml solution for injection

Indicated for: breast cancer

Route of administration: injectable

Substance: eribulin (antineoplastic agent)

ATC: L01XX41 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Eribulin is a chemotherapy medication used in the treatment of certain types of cancer, especially advanced breast cancer or liposarcoma. It works by inhibiting cell division, which stops the growth and multiplication of cancer cells.

Eribulin is administered by intravenous infusion at intervals determined by the oncologist, usually once every few weeks. The dose and frequency of treatment are tailored to each patient, depending on the response to therapy and any associated conditions.

Side effects may include fatigue, nausea, vomiting, decreased blood cell counts, hair loss, or, rarely, severe allergic reactions. Medical monitoring is essential throughout the treatment to manage possible complications.

Eribulin is an important option for patients with advanced cancer, offering the chance to slow disease progression and improve quality of life.

General data about ERIBULIN EVER PHARMA 0.44mg / ml

  • Substance: eribulin
  • Date of latest medicines list: 01-06-2026
  • Product code: W70422001
  • Concentration: 0.44mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 1
  • Product type: Generic medicine
  • Price: 517.62 RON
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: ONCOMED MANUFACTURING A.S - REPUBLICA CEHA
  • Holder: EVER VALINJECT GMBH - AUSTRIA
  • Number: 15522/2024/01
  • Shelf life: 3 years-after packing for marketing;after the first opening of the bottle-it is used immediately